The study received a lot of press
Respuesta Rpida: La semaglutida acta como un anlogo del GLP-1 que estimula la secrecin de insulina dependiente de glucosa, suprime el glucagn, retrasa el vaciamiento gstrico y reduce el apetito mediante receptores en pncreas, cerebro y tracto gastrointestinal
Those included various baseline characteristic including demographics (age, gender, race), comorbidities (e.g., liver diseases, chronic lower respiratory diseases, diabetic complications, obesity and neoplasm), medications (e.g., insulin, metformin, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), tacrolimus, cyclosporine, mycophenolate mofetil (MMF), and corticosteroids), as well as laboratory tests and physical findings (e.g., hemoglobin, glycated hemoglobin (HbA1c) levels, lipid profile, estimated glomerular filtration rate (eGFR) and systolic blood pressure (SBP))
A: Unlike many drugs, Dihexa dosing isn't typically weight-adjusted in research protocols
Blood 142, 1139
